ABSTRACT
The aim of the study is to determine the diagnostic utility of several islet autoantibodies and their combinations in order to identify individuals susceptible to type 1 diabetes mellitus (T1DM) among healthy siblings in the pediatric population within the scope of the development of a screening program. MATERIALS AND METHODS: A total of 424 children were evaluated, 260 children with new-onset T1DM and 164 healthy children with brothers and/or sisters with T1DM.Blood tests for a complex of autoantibodies to insulin (IAA), tyrosine phosphatase (IA-2A), zinc transporter 8 (ZnT8A), pancreatic ß-cells (ICA), and glutamate decarboxylase (GADA) were conducted in all the subjects with the enzyme immunoassay method. RESULTS: It was found that the diagnostic utility of individual autoantibodies is not equal and varies with age. The optimal age groups for the immunological control of the risks of developing type 1 diabetes in healthy siblings were determined. The highest risks were noted with the combination of GADA, ZnT8A, and IA-2A. CONCLUSION: Islet autoantibodies may serve as prognostic markers of the risk of developing type 1 diabetes in healthy siblings.
Subject(s)
Diabetes Mellitus, Type 1 , Islets of Langerhans , Autoantibodies , Child , Diabetes Mellitus, Type 1/diagnosis , Glutamate Decarboxylase , Humans , Male , SiblingsABSTRACT
AIM: To evaluate the efficiency of using the vitamin and mineral complex (VMC) ALFAVIT Diabetes in the combination therapy of diabetic polyneuropathy (DPNP) in adolescents. SUBJECTS AND METHODS: A study group comprised 30 children with diabetic peripheral polyneuropathy, whose combination therapy included ALFAVIT Diabetes as one tablet t.i.d. for 2 months. A comparison group consisted of 20 adolescents with DPNP who did not take the complex. Before and 2 months after the study, the children's state was assessed from the data of a physical examination with mandatory blood pressure and pulse measurements and a neurological study, from carbohydrate (basal glycemia, glycemic variability, glycated hemoglobin) and lipid (total cholesterol and its fractions) metabolic parameters, and from the findings of electromyography (EMG). RESULTS: Incorporation of the VMC ALFAVIT Diabetes into the combination therapy contributed to the ameliorated clinical manifestations of DPNP. There were positive electrophysiological changes, as evidenced by EMG. The VMC ALFAVIT Diabetes showed good tolerability and caused no adverse reactions. CONCLUSION: The performed trials have indicated that it is expedient to use the VMC ALFAVIT Diabetes in adolescents with type 1 diabetes mellitus and DPNP.
